Oncology is the largest and most consistently active therapeutic area in global healthcare private equity, venture capital and strategic M&A. The structural investment case rests on four durable foundations: rising incidence of cancer globally and in the UK, the accelerating pace of therapeutic innovation creating investable inflection points, favourable regulatory pathways for oncology innovations in both the UK and EU, and the scale of the market — measured in both patient population and addressable commercial opportunity — that supports meaningful returns across multiple investment strategies.

The European cancer therapy market was valued at $61.46 billion in 2025 and is projected to reach $64.72 billion in 2026, expanding to $83.69 billion by 2031 at a CAGR of 5.31%. This trajectory is supported by regulatory harmonisation by the European Medicines Agency, the expansion of precision medicine under the EU Beating Cancer Plan, and sustained R&D investment across Germany, France and the United Kingdom. Source: Mordor Intelligence, April 2026.

The United Kingdom is a particularly significant oncology investment geography. Cancer Research UK recorded over 360,000 new cancer cases in the UK in 2023, with breast, prostate and lung cancers the most prevalent. The NHS plays a central role in shaping oncology care delivery — but private capital is increasingly active in the spaces adjacent to NHS provision: specialist diagnostics, precision oncology platforms, digital pathology, radiotherapy infrastructure and pharmaceutical services supporting oncology drug development. Post-Brexit, the MHRA has streamlined pathways for accelerated assessments, enabling faster UK launches of novel oncology therapies and creating additional demand for UK-based regulatory and commercial services.

The therapeutic innovation pipeline is the primary driver of oncology investment activity — and in 2026, two technology platforms are commanding the most significant investor and strategic attention.

Antibody-drug conjugates (ADCs)

ADCs — which combine the targeted delivery of antibody therapies with the cytotoxic payload of chemotherapy — are the most actively invested class in oncology drug development in 2026. Antibody-drug conjugates are advancing at a 7.05% CAGR over 2026–2031 in the European oncology market. Major deals in the ADC space in early 2026 include Pfizer's commitment of $1.25 billion upfront and up to $4.8 billion in milestones for ex-China rights to 3SBio's SSGJ-707, a PD-1xVEGF bispecific. For investors, ADC platforms with differentiated chemistry and meaningful clinical data represent some of the highest-premium acquisition targets in pharma M&A.

Immuno-oncology and PD-1/PD-L1 inhibitors

PD-1 and PD-L1 inhibitor therapies held 31.55% of the European cancer therapy market share in 2025 — the largest single drug class segment. While the core checkpoint inhibitor market is now dominated by established players including Bristol-Myers Squibb, Merck and AstraZeneca, the competitive landscape in next-generation bispecific formats remains open and investable. BNP/BioNTech's bispecific candidate is competing with Summit Therapeutics' in a race that investors are watching closely.

Precision medicine and biomarker-driven development

Pipeline momentum increasingly favours biomarker-selected treatments — therapies designed for specific patient populations identified through genetic or molecular profiling. The pace of innovation in oncology remains strong, with truly differentiated clinical profiles continuing to command elevated premiums. Investors backing precision oncology platforms — particularly those with proprietary biomarker diagnostics paired with companion therapeutics — are positioning for both exit premium and strategic acquirer interest.

Financial and strategic interest will continue to prioritise therapeutic areas that can reset standards of care, with oncology seeing healthy M&A activity in 2026. Premiums for innovation will continue and likely accelerate — truly differentiated clinical profiles continue to command elevated premiums, with scarcity value and competitive processes producing outsized pricing for assets with meaningful patient benefits, clear regulatory paths and credible commercial ramps.

The acquisition of OneOncology — a physician-led oncology network — by Cencora at a $7.4 billion valuation, buying out private equity firm TPG's interest, signals the continued strategic appetite for oncology platform assets at scale. The transaction structure — where Cencora assumes majority ownership while affiliated practices and management retain a minority stake — reflects the governance model that has proven most effective for maintaining clinical culture through a private equity transition.

CAR-T cell therapy, as a specific segment, is expected to reach $7.6 billion in market value by 2026, representing a 39.1% CAGR since 2021 — making it one of the highest-growth segments within the broader oncology investment landscape. Source: Cascade Partners, December 2025.